K2 Principal Fund’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

K2 Principal Fund’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-14,500	Closed	-$1.49M	–	317
2023 Q2	$1.49M	Sell	14,500 -5,800	-29%	-$612K	0.34%	66
2023 Q1	$2.22M	Buy	+20,300	New	+$2.24M	0.3%	80
2018 Q1	–	Sell	-11,074	Closed	-$162K	–	394
2017 Q4	$162K	Sell	11,074 -8,926	-45%	-$125K	0.01%	261
2017 Q3	$254K	Buy	+20,000	New	+$254K	0.02%	281

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HBK Investments Dallas, Texas $10.3B AUM 67.69% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

K2 Principal Fund's HZNP Position: Q3 2023 in Review

K2 Principal Fund sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2023, closing a stake of 14,500 shares — an estimated $1.49M sold.

K2 Principal Fund first reported a position in HZNP in Q3 2017 and held it in 4 quarters. The position peaked at $2.22M in Q1 2023. 485 funds tracked by Wall St. Rank hold HZNP as of Q3 2023.

K2 Principal Fund reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2023 after selling out during the quarter.
K2 Principal Fund sold 14,500 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2023, an estimated $1.49M.
K2 Principal Fund first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2017 and held it in 4 quarters.
K2 Principal Fund's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $2.22M in Q1 2023.
485 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2023.

Based on K2 Principal Fund's 13F filing for Q3 2023, filed 13 Nov 2023.